Martin Faehling

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study

Follow-up algorithm for detecting chronic sequelae of pulmonary embolism: diagnostic performance and possible limitations

1980P Tumor mutational burden (TMB) and proliferation as negative prognostic factors for ALK+ lung cancer: First results from the randomized ABP phase II trial

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations

Estimated annual healthcare costs after acute pulmonary embolism: results from a prospective multicentre cohort study

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study

The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases

PACIFIC subgroup analysis: pneumonitis in stage III, unresectable NSCLC patients treated with durvalumab vs. placebo after CRT

Outcomes of patients = 70 years of age in PACIFIC

Erweiterte Sicherheits- und Wirksamkeitsanalyse von PACIFIC basierend auf dem Cutoff einer 25% PD-L1 Expression

Effekt einer Induktions-Chemotherapie in der PACIFIC-Studie

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer: The FORCE trial

PACIFIC: eine doppelblinde, Placebo-kontrollierte Phase-III-Studie zu Durvalumab als Konsolidierungstherapie nach einer Strahlenchemotherapie bei Patienten mit lokal fortgeschrittenem, inoperablem NSCLC

Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial